The SAVE Moms and Babies Act of 2026 significantly restricts how abortion medications can be approved and used in the United States. The bill prevents the FDA from approving any new abortion drugs and blocks experimental access to these medications. For the one abortion drug currently approved (mifepristone), the bill imposes strict new rules: it can only be used up to 70 days of pregnancy, must be administered in-person by a doctor in a medical clinic or hospital (never by mail or at a pharmacy), and cannot be dispensed by pharmacists. Doctors who prescribe this medication must meet specific requirements, including the ability to diagnose ectopic pregnancies, handle complications like incomplete abortions or severe bleeding, and ensure patients can access blood transfusions if needed. The bill requires extensive reporting of any deaths or serious health problems to the FDA, and doctors must give patients written information about risks and get their signed acknowledgment. Essentially, this legislation transforms abortion medication from a drug that can be prescribed and mailed like many others into a highly restricted medication that must be administered directly by specially trained doctors in clinical settings, with extensive safety monitoring and reporting requirements.